Aeterna Zentaris Announces It Has Licensed Exclusive Worldwide Rights To Develop, Manufacture And Commercialize Targeted, Highly Specific, Autoimmunity Modifying Proteins For The Potential Treatment Of MOSD From The Julius-Maximilians-University Wuerzburg